For laboratory research use only. Not for human or veterinary use.
TIRZEPATIDE

FOR RESEARCH USE ONLYNot for human or veterinary use of any kind
Full label. Lot number and expiry differ per batch and are printed on each vial.
GLP-1s & Amylin AnalogsPopular Research Peptides
Tirzepatide
Also known as: LY3298176
Tirzepatide is a synthetic dual-agonist peptide designed to bind and activate both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor.
- CAS
- 2023788-19-2
- M.W.
- 4,813.45 g/mol
- Formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- Form
- Lyophilized powder
$65.00per vial
Price shown per vial. Quantity discounts below.
In stock
Buy more, pay less per vial
Add 1 more vial to save 3%: $63.05 per vial.
- Safe credit card paymentVisa, Mastercard and American Express
- 30-day money-back guarantee
- Super-fast 1-2 day shippingTo all 50 states and DC
- Free shipping on orders over $200Applied automatically at checkout

Tirzepatide
5 mg · $65.00/vial
Lyophilized Tirzepatide storage
Lyophilized Tirzepatide peptide should be stored in a dry place, protected from sunlight and moisture.
The following storage conditions are generally recommended:
- Room temperature (15-25 °C / 59-77 °F): Up to ~3-8 months
- Refrigerated (2-8 °C / 35.6-46.4 °F): Up to 6 months
- Frozen (-20 °C / -4 °F or below): 3-5 years
Prior reconstituting with a suitable solvent or Saline, allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Reconstituted Tirzepatide storage
Once in solution, Tirzepatide is generally less stable compared to their lyophilized (powdered) form and should be stored at cold temperatures when possible.
These storage conditions are generally recommended:
- Room temperature (15-25 °C / 59-77 °F): Avoid longer than 2-4 day storage
- Refrigerated (2-8 °C / 35.6-46.4 °F): Typically 4-8 weeks
- Frozen (-20 °C / -4 °F or below): Up to 3-4 months
However, to preserve peptide efficacy and amino-acid bonds, avoid repeatedly freezing and unfreezing the peptide.
Tirzepatide delivery and shipping
Tirzepatide ships from US stock to United States addresses only. Orders are packed and dispatched within 1-2 business days.
- Standard: $9.95, 1-2 business days after dispatch.
- Express: $24.95, next business day after dispatch.
Lyophilized Tirzepatide ships in a sealed glass vial with protective packaging. The dry powder is stable at room temperature for the length of domestic transit, so no cold pack is needed. Move it to the storage conditions above when it arrives.
Follow your parcel any time on the Track Order page.
Tirzepatide lab testing and COA
The certificate of analysis for Tirzepatide is being uploaded. Ask support for the current report before you order if you need it now.
Every vial label has a lot number. Check it on the Verify page to confirm the vial is genuine. All reports are on the Lab Reports page.
For laboratory research use only. All products are sold for laboratory research use only. They are not drugs, foods, cosmetics or dietary supplements, and are not for human or veterinary use.
Tirzepatide specifications
- Product
- Tirzepatide
- Also known as
- LY3298176
- Compound class
- GLP-1s & Amylin Analogs
- Product type
- Peptide
- Form
- Lyophilized powder
- Amounts available
- 5 mg ($65.00), 10 mg ($109.00), 15 mg ($159.00), 30 mg ($279.00)
- Sequence
- H-Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-γ-Glu-(AEEA)₂-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
- Molecular weight
- 4,813.45 g/mol
- Molecular formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- CAS number
- 2023788-19-2
- Storage as supplied
- Sealed, dry, dark; -20 °C for long-term storage
- Lab report
- COA on request
- Research areas
- GLP-1s & Amylin Analogs, Popular Research Peptides
- Intended use
- Laboratory research only. Not for human or veterinary use.
Research overview
About Tirzepatide
Scientifically reviewed by John Johnson · Updated November 2026Tirzepatide is a synthetic dual-agonist peptide designed to bind and activate both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor.
This dual-receptor activity, confirmed through pharmacological data, distinguishes tirzepatide structurally and mechanistically from single-receptor GLP-1 analogs, positioning it as a compound of significant interest in current incretin biology and metabolic signaling research.
There is a considerable amount of literature available on the use of tirzepatide, which includes studies focusing on GIP and GLP-1 receptor activation and downstream signaling, as well as glucose-dependent insulin release mechanisms and suppression of glucagon release.
Tirzepatide is a synthetic dual agonist that targets both GIP and GLP-1 receptors, making it a widely researched peptide both in GIP and GLP-1 studies. Its dual-incretin mechanism has made it an important research subject for glucose homeostasis studies, insulin secretion pathways, and energy metabolism in laboratory settings.
What Is Tirzepatide?
Tirzepatide is a synthetic research peptide developed to stimulate the receptors for two of the incretin hormones that occur in nature: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)
This dual-receptor activity is its defining research characteristic, making it different from the GLP-1-based compounds studied in metabolic studies. The roles of incretin pathways in the processes of glucose-dependent secretion of insulin, glucagon regulation, gastrointestinal activity, and weight regulation make tirzepatide a compound across these interconnected systems.
Structurally, tirzepatide also incorporates a fatty-diacid moiety that promotes albumin binding, a feature associated with extended biological persistence in circulation. [1]
Tirzepatide Research Applications
As a tirzepatide research peptide, several areas of metabolic science have been examined using data originating solely from scientific studies and not from product claims:
- Dual incretin signaling: activation process of GIP and GLP-1 receptors at the same time and effects [2]
- Glucose metabolism: Research into insulin secretion depending on glucose and how glucagon signaling works. [3]
- Energy-balance pathways: Tirzepatide is studied using different experimental models focused on appetite control, food consumption, and energy-balance signaling. [4]
- Gastric physiology: Research into incretin-mediated effects on gastric emptying rates. [5]
- Insulin sensitivity: Investigated in clinical research contexts for its effects on insulin sensitivity. [6]
- Cardiometabolic research: More general investigation of metabolic and cardiovascular biomarkers in the study populations. [7]
These areas reflect documented research directions, not therapeutic or outcome guarantees associated with any specific product.
Tirzepatide FAQ
What is Tirzepatide?
Tirzepatide is a synthetic peptide that activates receptors for GIP and GLP-1, two incretin hormones involved in glucose regulation, insulin signaling, and energy-balance pathways studied in metabolic research.
Is Tirzepatide a GLP-1 peptide?
Tirzepatide activates GLP-1 receptors, but it isn't a GLP-1-only compound. Its defining feature is dual agonism, simultaneously targeting GLP-1 and GIP receptors, distinguishing it from single-incretin peptides.
What is Tirzepatide studied for?
Tirzepatide is studied in models examining incretin-mediated glucose regulation, insulin secretion, gastric emptying, and energy-balance signaling, based strictly on published scientific literature.
Is RUOPeptides Tirzepatide the same as Mounjaro?
No. Mounjaro is an FDA-approved prescription medication for human use. RUOPeptides Tirzepatide is sold strictly as a research compound, not as a substitute for Mounjaro.
Can RUOPeptides Tirzepatide be used for weight loss?
No. RUOPeptides Tirzepatide is sold exclusively for laboratory research and is not intended, labeled, or approved for human consumption or weight management.
Is RUOPeptides Tirzepatide the same as Zepbound?
No. Zepbound is an FDA-approved prescription product for human use. RUOPeptides Tirzepatide is a separate research compound, not affiliated with or equivalent to Zepbound.
Scientific references
- [1]LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- [2]Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- [3]Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test
- [4]Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
- [5]The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists
- [6]Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
- [7]The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
Buying Tirzepatide for research in the USA
Price
From $65.00. 5 mg: $65.00, 10 mg: $109.00, 15 mg: $159.00, 30 mg: $279.00. Quantity discounts per size: 3% off 2 vials, 5% off 3-4 vials, 7% off 5+ vials.
Shipping
US addresses only. Orders are packed and dispatched within 1-2 business days. Standard from $9.95.
Proof it's genuine
Check the lot number on your vial on the Verify page.
Lab reports
COA and SDS documents are on the Lab Reports page.
Scientifically reviewed
Scientifically reviewed by John Johnson
Scientific reviewer · Last reviewed November 2026
John Johnson reviewed this Tirzepatide page for scientific accuracy: the compound's identity and specifications, the summaries of published studies, and the references they cite. The page describes laboratory and preclinical research only. It is not medical advice and gives no usage guidance.
Research information on this page summarizes published laboratory and preclinical studies. It is not usage guidance.



